+

WO2000047197A3 - Agents d'alkylation destines au traitement de proliferation cellulaire - Google Patents

Agents d'alkylation destines au traitement de proliferation cellulaire Download PDF

Info

Publication number
WO2000047197A3
WO2000047197A3 PCT/US2000/003667 US0003667W WO0047197A3 WO 2000047197 A3 WO2000047197 A3 WO 2000047197A3 US 0003667 W US0003667 W US 0003667W WO 0047197 A3 WO0047197 A3 WO 0047197A3
Authority
WO
WIPO (PCT)
Prior art keywords
cellular proliferation
treatment
alkylating agents
alkylating agent
restenosis
Prior art date
Application number
PCT/US2000/003667
Other languages
English (en)
Other versions
WO2000047197A2 (fr
Inventor
Angelica Alvarado
Robert Eury
Irina D Pomerantseva
Michael Froix
Original Assignee
Quanam Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quanam Medical Corp filed Critical Quanam Medical Corp
Priority to AU35947/00A priority Critical patent/AU3594700A/en
Priority to EP00914574A priority patent/EP1150670A2/fr
Priority to JP2000598150A priority patent/JP2002536406A/ja
Priority to CA002362883A priority patent/CA2362883A1/fr
Publication of WO2000047197A2 publication Critical patent/WO2000047197A2/fr
Publication of WO2000047197A3 publication Critical patent/WO2000047197A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une méthode d'inhibition de prolifération cellulaire associée à une condition d'hyperprolifération telle que la resténose. Cette méthode consiste à administrer un agent d'alkylation. L'invention concerne aussi un extenseur destiné à administrer l'agent localement.
PCT/US2000/003667 1999-02-12 2000-02-10 Agents d'alkylation destines au traitement de proliferation cellulaire WO2000047197A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU35947/00A AU3594700A (en) 1999-02-12 2000-02-10 Alkylating agents for treatment of cellular proliferation
EP00914574A EP1150670A2 (fr) 1999-02-12 2000-02-10 Agents d'alkylation destines au traitement de proliferation cellulaire
JP2000598150A JP2002536406A (ja) 1999-02-12 2000-02-10 細胞増殖の治療用アルキル化剤
CA002362883A CA2362883A1 (fr) 1999-02-12 2000-02-10 Agents d'alkylation destines au traitement de proliferation cellulaire

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11995199P 1999-02-12 1999-02-12
US60/119,951 1999-02-12

Publications (2)

Publication Number Publication Date
WO2000047197A2 WO2000047197A2 (fr) 2000-08-17
WO2000047197A3 true WO2000047197A3 (fr) 2001-04-05

Family

ID=22387376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/003667 WO2000047197A2 (fr) 1999-02-12 2000-02-10 Agents d'alkylation destines au traitement de proliferation cellulaire

Country Status (5)

Country Link
EP (1) EP1150670A2 (fr)
JP (1) JP2002536406A (fr)
AU (1) AU3594700A (fr)
CA (1) CA2362883A1 (fr)
WO (1) WO2000047197A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625410B2 (en) 2001-05-02 2009-12-01 Boston Scientific Scimed, Inc. Stent device and method

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123469A1 (en) * 2000-10-31 2002-09-05 Brown Dennis M. Antiproliferative colchicine compositions and uses thereof
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US7018371B2 (en) 2001-05-07 2006-03-28 Xoft, Inc. Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia
US6537195B2 (en) 2001-05-07 2003-03-25 Xoft, Microtube, Inc. Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012846A1 (fr) * 1990-02-26 1991-09-05 Slepian Marvin J Procede et appareil de traitement d'organes tubulaires
WO1998008566A1 (fr) * 1996-08-30 1998-03-05 Duke University Manipulations de stress nitrosant et oxydatif dans le traitement d'une maladie
WO1998052944A1 (fr) * 1997-05-19 1998-11-26 Sugen, Inc. Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases
WO1998057671A2 (fr) * 1997-06-18 1998-12-23 Boston Scientific Corporation Dispersions de polycarbonate-polyurethane pour revetements thromboresistants
WO1999001118A2 (fr) * 1997-07-01 1999-01-14 Atherogenics, Inc. Amelioration au moyen d'antioxydants de la therapie destinee aux etats d'hyperproliferation
EP0970711A2 (fr) * 1998-06-30 2000-01-12 Ethicon, Inc. Procédé de revêtement d'extenseurs vasculaires

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012846A1 (fr) * 1990-02-26 1991-09-05 Slepian Marvin J Procede et appareil de traitement d'organes tubulaires
WO1998008566A1 (fr) * 1996-08-30 1998-03-05 Duke University Manipulations de stress nitrosant et oxydatif dans le traitement d'une maladie
WO1998052944A1 (fr) * 1997-05-19 1998-11-26 Sugen, Inc. Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases
WO1998057671A2 (fr) * 1997-06-18 1998-12-23 Boston Scientific Corporation Dispersions de polycarbonate-polyurethane pour revetements thromboresistants
WO1999001118A2 (fr) * 1997-07-01 1999-01-14 Atherogenics, Inc. Amelioration au moyen d'antioxydants de la therapie destinee aux etats d'hyperproliferation
EP0970711A2 (fr) * 1998-06-30 2000-01-12 Ethicon, Inc. Procédé de revêtement d'extenseurs vasculaires

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625410B2 (en) 2001-05-02 2009-12-01 Boston Scientific Scimed, Inc. Stent device and method

Also Published As

Publication number Publication date
WO2000047197A2 (fr) 2000-08-17
EP1150670A2 (fr) 2001-11-07
AU3594700A (en) 2000-08-29
CA2362883A1 (fr) 2000-08-17
JP2002536406A (ja) 2002-10-29

Similar Documents

Publication Publication Date Title
DE69900689D1 (en) Topoisomerase inhibitoren zur restenose-prevention
AU5056300A (en) Devices and compounds for treating arterial restenosis
AU5722800A (en) Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes
WO2003045333A3 (fr) Traitement de maladies hyperproliferatives au moyen d'analogues de vitamine d active
CA2367209A1 (fr) Catheter a ballonnet et catheter a ballonnet securitaire
MX9606131A (es) Agentes neuroprotectores.
AU4975500A (en) Stent having antimicrobial agent
WO2002056912A3 (fr) Methode de traitement du cancer
AU2003225802A1 (en) 40-o-(2-hydroxy)ethyl-rapamycin coated stent
WO1998048852A3 (fr) Tuteurs a revetement polymere
EP0963757A3 (fr) Agent hémostatique
AU3626895A (en) Quinazolinone pharmaceuticals and use thereof
WO2003018083A3 (fr) Composition de revetement pour une endoprothese d'administration de medicaments et une endoprothese d'administration de medicaments fabriquee en faisant appel a ladite composition de revetement
GEP20094818B (en) 2-methyl-thieno-benzodiaze-pine formulation
WO2000047197A3 (fr) Agents d'alkylation destines au traitement de proliferation cellulaire
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
SG92610A1 (en) The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of neointima formation, restenosis, and arteriosclerosis
WO2000024387A3 (fr) Methode de prevention, d'elimination, d'attenuation et de traitement de la cystite radique au moyen d'acide hyaluronique
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
HK1028520A1 (en) Charger for radio telephone set.
WO2000069841A3 (fr) Benzofuranylaminoalcools
AU3290200A (en) Treatment agents for textiles, method of producing same and their use
WO2000071106A3 (fr) Methode de traitement
ZA200005575B (en) Preparation of an aqueous composition for treating leather.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2362883

Country of ref document: CA

Ref country code: CA

Ref document number: 2362883

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 598150

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000914574

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000914574

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000914574

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载